Login to Your Account

Amylin Takes Hit After Two Deaths Are Linked to Byetta

By Donna Young

Wednesday, August 20, 2008
Amylin Pharmaceuticals Inc.'s stock took a hit again Tuesday following Monday's 13 percent drop after the late afternoon revelation by the FDA that two patients taking the firm's Type II diabetes product Byetta (exenatide) died of acute pancreatitis and four other patients were hospitalized with the illness. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription